Justice Black has confirmed in his written reasons for judgment in Re Nexus Energy Ltd (subject to deed of company arrangement)  NSWSC 1910 the utility of section 444GA to achieve debt for equity restructures of listed companies.
The Australian Competition and Consumer Commission (ACCC) launches 2015 Compliance and Enforcement Policy at CEDA in Sydney. This policy provides valuable insight into the ACCC’s enforcement priorities for the year ahead.
On 13 February ASIC issued a stop order prohibiting Bitcoin Group Limited (a Bitcoin miner) from publishing statements concerning its intention to make an initial public offering of its shares on the ASX until it has formally lodged a prospectus.
A look into the future of NFC and NFC uptake in Australia (a world leading proponent of NFC technology) including payment systems, banking, retail and transport applications. From Opal cards to credit cards – this surprisingly versatile technology has seemingly endless uses in the digital age.
Internet data retention is back on the political agenda.The Telecommunications (Interception and Access)Amendment (Data Retention) Bill 2014 (Cth) was tabled by the Minister for Communications, Malcolm Turnbull MP, in the Australian parliament on 30 October 2014. The controversy started immediately.
On Wednesday 14 January 2015, the Minister for Small Business announced the release of Exposure Draft legislation and regulations containing amendments to the taxation arrangements of Employee Share Schemes (ESS) previously announced in October 2014.
This report provides an overview of the Office of the Australian Information Commissioner’s (‘OAIC’) eHealth compliance and enforcement activities. First published in eHealth Law & Policy – January 2015.
A recent decision of the Appeals Panel of the NSW Civil & Administrative Tribunal has confirmed the broad reach of the Privacy and Personal Information Protection Act 1998 (NSW) (PPIP Act), and the nature of personal information which it protects.
The Full Federal Court in AstraZeneca AB v Apotex Pty Ltd has upheld the trial judge’s finding that AstraZeneca patents relating to its blockbuster drug CRESTOR are invalid. The key issue on appeal, and the reason the Full Court agreed to sit as an enlarged bench, related to determination of the appropriate “starting point”, if any, for assessing inventive step. This was first published in the Australian Intellectual Property Law Bulletin (2014) 27(10) IPLB.